Table 2 - uploaded by Marc Miravitlles
Content may be subject to copyright.
Source publication
Purpose:
Several studies have analyzed factors associated to hospitalization in chronic obstructive pulmonary disease (COPD) patients. However, data are lacking on the quality of treatment received by patients prior to hospital admission. The present study analyzed how often patients requiring hospitalization for a COPD exacerbation had received p...
Similar publications
Introduction: Chronic obstructive pulmonary disease (COPD) and bronchiectasis share common pathophysiological, clinical and functional characteristics, and can exist simultaneously. This comorbidity is recently examined and there is a need for more data on the interaction between the two conditions.
Aim: To assess how the accompanying bronchiectasi...
OBJECTIVES: To estimate the economic impact of the introduction of budesonide/formoterol fixed-dose combination (FDC) with a new inhaler, Spiromax®, focusing on an increment of medication compliance due to an enhancement of the inhalation technique for the treatment of Chronic Obstructive Pulmonary Disease (COPD) patients in five Spanish regions in...
Background: Acute exacerbations form a major component of the socioeconomic burden of COPD. As yet, little information is available about the long-term outcome of patients who have been hospitalized with acute exacerbations, although high mortality rates have been reported. The aim of this study was to determine predictors of long-term mortality af...
Background
While different COVID-19 vaccines have been developed, there has been lack of data on the efficacy comparison between mRNA and inactivated whole virus vaccine among patients with chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis.
Methods
This was a retrospective case control...
Objective: Bronchiectasis is an important cause of morbidity and mortality all over the world and it still a real challenge in areas that lack to healthy conditions. was to evaluate the efficacy of O'Donnell criteria as a predictor of poor prognosis in hospitalized patients with acute exacerbation of bronchiectasis (AEB). Methods: This study is obs...
Citations
... In the past, long-term administration of antibiotics was used to treat acute exacerbations of COPD, but metaanalyses of the studies of antibiotic administration showed no significant benefit (2). A multicenter, crosssectional, observational study was conducted in 30 Spanish hospitals among COPD patients aged > 40 years who were hospitalized for an acute exacerbation showed that antibiotic use was significantly associated with yellow or green-yellow sputum prior to the exacerbation, a higher number of exacerbations in the previous year, more visits to emergency departments, and bronchiectasis (3). Because of these problems with antibiotic treatment, more and more traditional Chinese physicians are focusing on exploring the therapeutic effect of Chinese herbal medicine in COPD. ...
The chronic course and evolution of chronic obstructive pulmonary disease (COPD) is often characterized by periods of exacerbation of symptoms, which have a negative impact on the quality of life of patients, as well as on the evolution of COPD, and represent a significant cause of medical intervention and hospitalization. Very few data are available on the efficacy of rescue antibiotics in patients with acute exacerbation of COPD (AECOPD) unresponsive to previous treatment. The aim of this study was to evaluate the efficacy of two fluoroquinolones in AECOPD previously treated without success. The FADOI-FLOR study is a randomized, single-blind, non-inferiority comparison between levofloxacin and prulifloxacin. Primary end-point was "therapeutic success" at Day 10 of treatment, defined as disappearance of signs/symptoms or decrease of at least three points of a global score of symptomatology (maximum score = 15). 258 patients were enrolled (128 levofloxacin and 130 prulifloxacin), in 25 centers. A very high proportion of patients in the two groups had therapeutic success at Day-10 (levofloxacin 93.0% vs prulifloxacin 96.7%, population intention-to-treat; 94.6% vs 99.1%, population per-protocol). Earlier therapeutic success (within 7 days) was achieved in 32.0% and 36.2% of patients receiving levofloxacin or prulifloxacin, respectively. At 3-month follow-up, re-exacerbations occurred in 17.8% of patients treated with levofloxacin and 14.2% of those receiving prulifloxacin (p = 0.44). In conclusion, fluoroquinolones are very effective in the treatment of AECOPD resistant to other antibiotics.
